Načítá se...
Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa
Direct factor Xa (FXa) inhibitors lack a specific reversal agent for emergencies such as major bleeding or urgent surgery. Andexanet alfa, a modified, catalytically inactive, recombinant human FXa derivative, reverses anticoagulant effect by binding and sequestering FXa inhibitors. This original rep...
Uloženo v:
| Vydáno v: | Blood Adv |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society of Hematology
2017
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5728098/ https://ncbi.nlm.nih.gov/pubmed/29296829 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017007112 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|